PriceSensitive

Psyched Wellness (CSE:PSYC) provides update on study with the National Research Council of Canada

Health Care, Psychedelics
CSE:PSYC
26 January 2022 12:45 (EDT)

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).

Psyched engaged the NRC to provide their expertise in biomedical nanotechnology for the study.

The study has confirmed that the company’s key proprietary extract, AME-1, holds anti-inflammatory properties.

AME-1 is extracted from the Amanita Muscaria mushroom, which Psyched Wellness is developing into water-based extracts to help promote stress relief, relaxation, and restful sleep.

The study is examining the anti-inflammatory properties of AME-1 by studying the effects of the extract on mast cells, which are important inflammatory cells present in the skin, gut, brain, and lungs.

Prior research performed by the NRC had already shown that AME-1 inhibited mast cell activation of histamine release.

This continued research has verified that pre-treatment of human mast cells with AME-1 results in the decrease of the release of pro-inflammatory mediators such as inflammatory cytokines.

“We are excited about these findings and the potential they may have to help sufferers of conditions such as arthritis,” remarked Jeff Stevens, CEO of Psyched Wellness. “We look forward to sharing more updates as additional studies are undertaken to further examine the mechanisms of the anti-inflammatory properties of the Amanita Muscaria mushroom.”

Psyched Wellness is a Canadian life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms.

Shares in Psyched Wellness Corp. (PSYC) are up 4.76 per cent, trading at $0.11 per share as of 12:20 pm EST.

Related News